- Home
- GILD vs MUFG Comparison
GILD vs MUFG Comparison
Compare GILD & MUFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MUFG
- Stock Information
- Founded
- GILD 1987
- MUFG 1880
- Country
- GILD United States
- MUFG Japan
- Employees
- GILD N/A
- MUFG N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MUFG Commercial Banks
- Sector
- GILD Health Care
- MUFG Finance
- Exchange
- GILD Nasdaq
- MUFG Nasdaq
- Market Cap
- GILD 144.1B
- MUFG 167.5B
- IPO Year
- GILD 1992
- MUFG 2001
- Fundamental
- Price
- GILD $115.05
- MUFG $15.29
- Analyst Decision
- GILD Buy
- MUFG
- Analyst Count
- GILD 23
- MUFG 0
- Target Price
- GILD $115.68
- MUFG N/A
- AVG Volume (30 Days)
- GILD 5.9M
- MUFG 3.4M
- Earning Date
- GILD 11-05-2025
- MUFG 08-04-2025
- Dividend Yield
- GILD 2.75%
- MUFG 2.30%
- EPS Growth
- GILD 496.80
- MUFG N/A
- EPS
- GILD 5.01
- MUFG 0.75
- Revenue
- GILD $28,863,000,000.00
- MUFG $37,710,895,911.00
- Revenue This Year
- GILD $2.01
- MUFG $2.31
- Revenue Next Year
- GILD $4.03
- MUFG $8.05
- P/E Ratio
- GILD $22.96
- MUFG $20.16
- Revenue Growth
- GILD 3.81
- MUFG N/A
- 52 Week Low
- GILD $77.74
- MUFG $9.85
- 52 Week High
- GILD $121.83
- MUFG $16.16
- Technical
- Relative Strength Index (RSI)
- GILD 52.20
- MUFG 55.65
- Support Level
- GILD $111.28
- MUFG $14.86
- Resistance Level
- GILD $118.13
- MUFG $15.43
- Average True Range (ATR)
- GILD 2.06
- MUFG 0.16
- MACD
- GILD -0.46
- MUFG -0.07
- Stochastic Oscillator
- GILD 39.23
- MUFG 49.42
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.